“O.itemList.length” “- this.config.text.ariaShown
“This.config.text.ariaFermé”
TORONTO, August 12, 2020 (GLOBE NEWSWIRE) – Datametrex AI Limited (the “Company” or “Datametrex”) (TSXV: DM, FSE: D4G, OTC: DTMXF) is pleased to announce that it has received the rights to sell and distributed the COV0five COVID19 Antigen Detection Kits from South Korean manufacturer PCL, Inc. These verification kits are suitable for point-of-service verification. No other appliance is required. They are easy to use with an accuracy of more than 97% and the effects are obtained in five to ten minutes.
The immediate antigen diagnostic kit developed by PCL is a fluorescence measurement method of the presence of COVID-19 infection. It is an in vitro medical diagnostic device for tripping over the SARS-CoV-2 antigen of a person’s oropharyngeal and nasopharyngeal secretions if the SARS-CoV-2 antigen pattern appears, a color line appears in the T-line area.
Check the PCL by clicking on the LINK PCL COVID-19 ANTIBODY TEST – COV0
“According to the PCL manufacturer, this verification may stumble upon the COVID-19 antigens of a nose or throat pattern and produce effects in 10 minutes with an accuracy of more than 97%,” said Marshall Gunter, CEO of Datametrex. “These almost instant kits can be used seamlessly at home. With accumulation in cases in the U.S. And all over the world, at Datametrex, it is essential to verify and protect them.”
PCL states that the clinical sensitivity (confirmed the actual positive of the approved person) is one hundred percent and the clinical specificity (confirmed the actual negative of the negative person) is 97.78%. Early detection with immediate testing will also provide greater coverage for frontline staff in Canada, i.e. health professionals.
The following certifications have been awarded to these PCL antigen verification kits: CE Certificate, Korean FDA, FIND Listing, UNGM Supplier. The countries come with the EU, 2 countries in the Middle East – Qatar and the United Arab Emirates, India, Russia, 3 Latin American countries – Guatemala, Ecuador and Colombia.
Worldwide, there are more than 19.7 million other people who have tested positive for COVID-19 lately, however, the actual number of cases is assumed to be higher, as a significant number of other asymptomatic people may not have been examined. More worryingly, maximum families had to wait more than 72 hours for their control effects to return to public and personal laboratories, expanding the option of spreading the virus.
The immediate diagnostic kit is simple when there are no symptoms even after a COVID-19 infection, or when “positive” and “negative” tests are not evident in tests such as RT-PCR. When an infection occurs, an antigen opposes the COVID-19 bureaucracy within the framework after a given time, so it is a subsequent test that is as a preventive measure.
The Company does not explicitly or implicitly make its product have the ability to remove, cure or involve COVID-19 (or SARS-2 coronavirus) at this time. Health Canada will need to approve these COVID-19 verification kits before they can be used in Canada. The company plans to sell these kits in all countries where the sale of the kits has been approved.
About Datametrex
Datametrex AI Limited is a technology-driven company with exposure to synthetic intelligence and device learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s project is to obtain equipment that helps companies achieve their operational goals, adding fitness and security, with predictive and preventive technologies. Working with corporations to outline a new popular protocol through synthetic intelligence and aptitude diagnostics, the company obtains progressive responses to the source chain. Additional information about Datametrex can be found at www.datametrex.com.
For information, contact: Marshall Gunter – CEOP Phone: (514) 295-2300 Email: [email protected]
Neither TSX Venture Exchange nor its regulatory service provider (as explained in TSX Venture Exchange policies) assumes the duty of the relevance or accuracy of this release.
Forward-looking statements
This press release “prospective data” within the meaning of applicable securities laws. Any statement contained in this document that is not old would possibly constitute forward-looking information. In some cases, prospective data may be known through words or words such as “possibly”, “will be,” “expect,” “likely,” “should,” “would,” “plan,” “anticipate,” “anticipate”, “potential”,” proposed “,” “estimate”,” believe “or the negative of those terms, or similar words, grammatical expressions and diversifications of those, or statements that certain occasions or conditions” may “or “occur”, or through strategic discussions.